Nutriband Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.33next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 Fiscal 2027 Earnings Release | 15 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Revenue Annually2M
Net Loss Annually-8.2M
Cash and Cash Equivalents Annually4.6M
Q1 Revenue Quarterly433.4K
Q1 Net Loss Quarterly-1.2M
Watch Items
- FDA IND Filing and Human Abuse Potential (HAP) Clinical Study InitiationTrigger: Submission of IND application to the FDA for AVERSA FentanylAction: Monitor SEC filings and press releases for regulatory updates regarding the clinical path.
- Pocono Subsidiary Divestiture CompletionTrigger: Receipt of $5 million cash from EarthVision Bio for 90% of PoconoAction: Verify cash inflow and balance sheet impact in subsequent quarterly reports.
- Warrant ExpirationTrigger: Expiration of 2021 IPO warrants on October 1, 2026Action: Assess potential dilution or cash inflows from warrant exercises prior to expiration.
Research as of 19 Jun 2026